Welcome to the e-CCO Library!

DOP71: Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Li*1, J. R. Friedman1, C. Marano1, H. Zhang1, F. Yang1, B. G. Feagan2, L. Peyrin-Biroulet3, G. De Hertogh4

Created: Friday, 22 February 2019, 9:41 AM
DOP71: Fungal and bacterial gut microbiota in paediatric onset Inflammatory Bowel Disease introduced to infliximab
Year: 2021
Source: ECCO'21 Virtual
Authors: Ventin-Holmberg, R.(1);Höyhtyä, M.(2);Saqib, S.(3);Korpela, K.(3);Nikkonen, A.(4);Salonen, A.(3);de Vos, W.M.(5);Kolho, K.L.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP71: Low occurrence of colectomy with long-term (up to 4 years) golimumab treatment in patients with moderate-to-severe active Ulcerative Colitis: Data from the PURSUIT maintenance and long-term extension studies
Year: 2022
Source: ECCO'22
Authors: Weinstein, C.L.(1);Meehan, A.G.(2);Lin, J.(3);Govoni, M.(4);Qureshi, Z.P.(5);
Created: Friday, 11 February 2022, 3:52 PM
DOP71: TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Saifuddin, A.(1)*;Madgwick, M.(2);Cozzetto, D.(1);Pavlidis, P.(3);Verstockt, B.(4,5);Hart, A.(1,6);Korcsmaros, T.(1);Powell, N.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Danese1, M. Klopocka2, E.J. Scherl3, J. Romatowski4, J.R. Allegretti5, E. Peeva6, M.S. Vincent6, U. Schoenbeck7, L. Xi6, Z. Ye6, M. Hassan-Zahraee6, N. Rath8, G. Li8, S. Neelakantan6, C. Banfield6, C. Lepsy9, D. Chandra6, K.E. Hung6

Created: Thursday, 30 January 2020, 10:12 AM
DOP72: HLA-DQA1*05 associates with immunogenicity and loss of response to anti-TNF therapy in the IBD population: A meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Elizabeth Spencer
Created: Friday, 14 July 2023, 2:22 PM
DOP72: HLA-DQA1*05 associates with immunogenicity and loss of response to anti-TNF therapy in the IBD population: A meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bergstein, S.(1)*;Spencer, E.A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. de Jong*1, H. Kanne1, L. Nissen2, I. Nagtegaal3, J. Drenth1, L. Derikx1,2, F. Hoentjen1

Created: Friday, 22 February 2019, 9:41 AM
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Michiel de Jong
Created: Tuesday, 28 May 2019, 3:32 PM
Crohn’s disease, Ulcerative colitis, Dysplasia, Dysplasia, Colorectal cancer
Files: 1
DOP72: Perianal Crohn’s Disease in the biologic era: A population-based cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Jenkinson, P.(1);Plevris, N.(1);Lyons, M.(1);Siakavellas, S.(1);Arnott, I.(1);Jones, G.R.(1);Watson, A.(2);Lees, C.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP72: Pregnancy for IBD-patients with an enterostomy is feasible but is associated with complications
Year: 2024
Source: ECCO'24 Stockholm
Authors: Bouwknegt, Dianne G.
Created: Tuesday, 30 April 2024, 5:03 PM
DOP72: The association of anti-tumor necrosis factor and thiopurine therapy with the risk of lymphoma among Inflammatory Bowel Disease patients: A nation-wide study from the epi-IIRN
Year: 2022
Source: ECCO'22
Authors: WatermanM.D, M.(1);Lavi, I.(2);Harel, S.(3);Focht, G.(4);Loewenberg Weisband, J.(5);Greenfeld, S.(6);Kariv, R.(6);Ledderman, N.(7);Matz, E.(8);Keinan-Boker, L.(9);Eizenstein, S.(10);Dotan, I.(11);Turner, D.(4);Levi, Z.(12);
Created: Friday, 11 February 2022, 3:52 PM
DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.E. Sands1, A.C. Moss2, A. Armuzzi3, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, M. Zeroncio8, I. Modesto9, L. Salese10, N. Lawendy10, H. Zhang10, C. Su10

Created: Thursday, 30 January 2020, 10:12 AM